Immunization with antigen-pulsed dendritic cells significantly improves the immune response to weak self-antigens
/in Dendritic Cells, International Publications /von 2006-01-18 / Immunobiology 2006;211(1-2):29-36Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70
/in Chronic Virus Hepatitis, International Publications /von 2006-01-18 / Vaccine 2006 Feb;24(7):887-96Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
/in International Publications, Malignant Melanoma /von 2006-01-17 / Ann. Oncol. 2006 Apr;17(4):563-70Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection
/in HIV/AIDS, International Publications /von 2006-01-09 / Proc. Natl. Acad. Sci. U.S.A. 2006 Jan;103(3):738-43Dendritic cell defects in patients with cancer: mechanisms and significance
/in Dendritic Cells, International Publications /von 2006-01-05 / Breast Cancer Res. 2006;8(1):101Quick generation of fully mature dendritic cells from monocytes with OK432, low-dose prostanoid, and interferon-alpha as potent immune enhancers
/in Gastric Cancer, International Publications /von 2006-01-01 / J. Immunother. 2006 Jan-Feb;29(1):67-77Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-37Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2006-01-01 / Cytotherapy 2006;8(3):277-89Immunotherapy for prostate cancer
/in International Publications, Prostate Cancer /von 2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-17
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution